Skip to main navigation
Instil Bio logo
  • Home
  • News & Events
    • News Releases
    • Events
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Proxy Materials
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR

News Releases

November 13, 2023
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 6, 2023
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
August 14, 2023
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
June 26, 2023
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
May 11, 2023
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
March 31, 2023
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
January 31, 2023
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
January 9, 2023
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Investor Tools

Instil Bio Instil Bio

Footer Menu

  • About
  • Careers
  • Pipeline
  • Contact Us
  • Publications

Site Social Media Links

  • LinkedIn LinkedIn
  • Twitter Twitter
© 2023 Instil Bio. All Rights Reserved
Privacy Policy Terms of Service Agency Policy